Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 9 Gy Clear all
Completed Not applicable Interventional

Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL

NCT03042585
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Total body irradiation
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

NCT00601705
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 31, 2026, 10:38 AM EDT
Completed No phase listed Observational

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery

NCT03095209
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer
Interventions
Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Suspended Phase 1 Interventional

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

NCT05403723
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959
View directory record Official record
Conditions
Breast Cancer
Interventions
Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy
Drug · Radiation
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

NCT04147806
View directory record Official record
Conditions
Prostate Cancer
Interventions
IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone, Tamsulosin
Radiation · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

NCT00513604
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
Interventions
aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide, Fludarabine phosphate, Total body irradiation
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 31, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT01532635
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
Radiation · Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Active, not recruiting Not applicable Interventional

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

NCT03643861
View directory record Official record
Conditions
Breast Cancer
Interventions
5 Fraction Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Stereotactic Body Radiotherapy for Head and Neck Tumors

NCT01344356
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma, Paraganglioma of Head and Neck, Chordoma of Head and Neck, Chondrosarcoma of Head and Neck, Angiofibroma of Head and Neck
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

NCT01146054
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 31, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

NCT01258868
View directory record Official record
Conditions
Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
Interventions
Celebrex, Tumor cell vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

NCT00185965
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Mycosis Fungoides
Interventions
CPG 7909
Drug
Lead sponsor
Ronald Levy
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

NCT01471067
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions
Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 31, 2026, 10:38 AM EDT
Recruiting Phase 2 Interventional

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

NCT06386315
View directory record Official record
Conditions
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
Interventions
Computed Tomography, Endoscopic Procedure, Involved-site Radiation Therapy (3 Fractions), Involved-site Radiation Therapy (12 Fractions), Positron Emission Tomography, Questionnaire Administration
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

NCT05574114
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
Interventions
Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product
Radiation · Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Stereotactic Radiosurgery in Treating Patients With Spinal Metastases

NCT00853528
View directory record Official record
Conditions
Metastatic Cancer
Interventions
questionnaire administration, diffusion tensor imaging, functional magnetic resonance imaging, hypo-fractionated SRS, single-fraction SRS
Other · Procedure · Radiation
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

NCT01401062
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fresolimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 31, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

NCT00216086
View directory record Official record
Conditions
Rectal Cancer
Interventions
Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
Drug · Procedure
Lead sponsor
Gabi Chiorean, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

NCT00186888
View directory record Official record
Conditions
Retinoblastoma, Retinal Neoplasm
Interventions
Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Recruiting Phase 1 Interventional

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

NCT07139990
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions
Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Recruiting Phase 1 Interventional

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TTI-101, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

NCT04683679
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 10:38 AM EDT